In last trading session, Immunome Inc (NASDAQ:IMNM) saw 0.67 million shares changing hands with its beta currently measuring 1.90. Company’s recent per share price level of $9.52 trading at -$0.59 or -5.84% at ring of the bell on the day assigns it a market valuation of $806.10M. That closing price of IMNM’s stock is at a discount of -225.21% from its 52-week high price of $30.96 and is indicating a premium of 5.78% from its 52-week low price of $8.97.
For Immunome Inc (IMNM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.67 in the current quarter.
Immunome Inc (NASDAQ:IMNM) trade information
Upright in the red during last session for losing -5.84%, in the last five days IMNM remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $9.52 price level, adding 10.86% to its value on the day. Immunome Inc’s shares saw a change of -10.36% in year-to-date performance and have moved -8.72% in past 5-day. Immunome Inc (NASDAQ:IMNM) showed a performance of -6.76% in past 30-days.
Wall Street analysts have assigned a consensus price target of 33 to the stock, which implies a rise of 71.15% to its current value. Analysts have been projecting 23 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -141.6% in reaching the projected high whereas dropping to the targeted low would mean a loss of -141.6% for stock’s current value.
Immunome Inc (IMNM) estimates and forecasts
This year revenue growth is estimated to fall -32.90% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 3.16M for the same. And 6 analysts are in estimates of company making revenue of 515.67k in the next quarter. Company posted 3.83M and 1.03M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -48.48% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 17.82% while estimates for its earnings growth in next 5 years are of 16.01%.
Immunome Inc (NASDAQ:IMNM)’s Major holders
REDMILE GROUP, LLC is the top institutional holder at IMNM for having 4.89 million shares of worth $59.16 million. And as of 2024-06-30, it was holding 8.1579 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 4.21 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.0257 of outstanding shares, having a total worth of $50.95 million.
On the other hand, Price (T.Rowe) Small Cap Stock Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 2.07 shares of worth $19.7 million or 3.31% of the total outstanding shares. The later fund manager was in possession of 1.64 shares on Sep 30, 2024 , making its stake of worth around $15.59 million in the company or a holder of 2.62% of company’s stock.
